• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    9/11/24 4:45:16 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email
    SC 13D/A 1 sc13d-a3.htm SCHEDULE 13D, AMENDMENT NO. 3

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549



    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)



    23ANDME HOLDING CO.
    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    90138Q108
    (CUSIP Number)
    ABEEC 2.0, LLC
    171 Main Street, Suite 259
    Los Altos, California 94022
    THE ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED
    Trustee Anne Wojcicki
    171 Main Street, Suite 259
    Los Altos, California 94022
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    Copies To:
    Graham Robinson
    Chadé Severin
    Skadden, Arps, Slate, Meagher & Flom LLP
    500 Boylston Street, 23rd Floor
    Boston, Massachusetts 02116
    September 9, 2024
    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box  ☐.
     


    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
     


    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.)
     



    1.
    Names of Reporting Persons
     
    ABeeC 2.0, LLC
    2.
    Check the Appropriate Box if a Member of a Group
    (a)  ☐        (b)  ☐
     
    3.
    SEC Use Only
     
    4.
    Source of Funds (See Instructions)
     
    N/A
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
    ☐
    6.
    Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares
     Beneficially 
    Owned by
    Each
    Reporting
    Person
    With 
    7.
    Sole Voting Power
     
    0
    8.
    Shared Voting Power
     
    98,633,827 (1)(2)(3) (see Item 5)
    9.
    Sole Dispositive Power
     
    0
    10.
    Shared Dispositive Power
     
    98,633,827 (1)(3) (see Item 5)
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    98,633,827 (3) (see Item 5)
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
    ☐
    13.
    Percent of Class Represented by Amount in Row (11)
     
    22.5% (4)
    14.
    Type of Reporting Person
     
    OO

     
    (1)
    The ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED (the “Trust”) is the sole member of ABeeC 2.0, LLC (the “LLC”) and Anne Wojcicki is the sole trustee of the Trust. Accordingly, the LLC, the Trust, and Ms. Wojcicki have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B common stock, par value $0.0001 per share (the “Class B Common Stock”) of 23andMe Holding Co. (the “Issuer”) held by the LLC.
    (2)
    The LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.
    (3)
    Represents shares of the Issuer’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) that may be obtained upon the conversion of shares of Class B Common Stock held by the reporting persons. Class B Common Stock, which is not registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is convertible into shares of Class A Common Stock on a share-for-share basis.
    (4)
    Based upon (a) 339,502,600 shares of Class A Common Stock outstanding as of July 31, 2024, as disclosed in the Issuer’s Quarterly Report for the quarterly period ended June 30, 2024 filed on Form 10-Q with the Securities and Exchange Commission (“SEC”) on August 8, 2024, and (b) 98,633,827 shares of Class A Common Stock issuable upon conversion of the Class B Common Stock held by the LLC.

    1



    1.
    Names of Reporting Persons
     
     THE ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED
    2.
    Check the Appropriate Box if a Member of a Group
    (a)  ☐        (b)  ☐
     
    3.
    SEC Use Only
     
    4.
    Source of Funds (See Instructions)
     
    N/A
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
    ☐
    6.
    Citizenship or Place of Organization
     
     California
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
    7.
    Sole Voting Power
     
    0
    8.
    Shared Voting Power
     
    98,633,827 (1)(2)(3) (see Item 5)
    9.
    Sole Dispositive Power
     
    0
    10.
    Shared Dispositive Power
     
    98,633,827 (1)(3) (see Item 5)
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    98,633,827 (3) (see Item 5)
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
    ☐
    13.
    Percent of Class Represented by Amount in Row (11)
     
    22.5% (4)
    14.
    Type of Reporting Person
     
    OO

     
     
    (1)
    Represents shares of Class B Common Stock held by LLC. The Trust is the sole member of the LLC and Ms. Wojcicki is the sole trustee of the Trust. Accordingly, the LLC, the Trust, and Ms. Wojcicki have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B Common Stock held by the LLC.
    (2)
    The LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.
    (3)
    Represents shares of the Issuer’s Class A Common Stock that may be obtained upon the conversion of shares of Class B Common Stock held by the reporting persons. The Class B Common Stock, which is not registered under the Exchange Act, is convertible into shares of Class A Common Stock on a share-for-share basis.
    (4)
    Based upon (a) 339,502,600 shares of Class A Common Stock outstanding as of July 31, 2024, as disclosed in the Issuer’s Quarterly Report for the quarterly period ended June 30, 2024 filed on Form 10-Q with the SEC on August 8, 2024, and (b) 98,633,827 shares of Class A Common Stock issuable upon conversion of the Class B Common Stock held by the LLC.

    2



    1.
    Names of Reporting Persons
     
     Anne Wojcicki
    2.
    Check the Appropriate Box if a Member of a Group
    (a)  ☐        (b)  ☐
     
    3.
    SEC Use Only
     
    4.
    Source of Funds (See Instructions)
     
     PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
    ☐
    6.
    Citizenship or Place of Organization
     
     United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
     
    7.
    Sole Voting Power
     
    9,378,354 (1)
    8.
    Shared Voting Power
     
    101,133,827 (2)(3)(4)(5)(6) (see Item 5)
    9.
    Sole Dispositive Power
     
    9,378,354 (1)
    10.
    Shared Dispositive Power
     
    101,133,827 (2)(3)(5)(6) (see Item 5)
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    110,512,181 (1)(2)(6) (see Item 5)
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
    ☐
    13.
    Percent of Class Represented by Amount in Row (11)
     
    24.8% (7)
    14.
    Type of Reporting Person
     
    IN


    (1)
    Includes (a) 1,094,257 shares of Class A Common Stock held directly by Ms. Wojcicki and (b) 8,284,097 stock options held by Ms. Wojcicki that have vested or will vest within sixty days of the date hereof.
    (2)
    Includes indirect beneficial ownership of (a) 98,633,827 shares of Class B Common Stock held by the LLC and (b) 2,500,000 shares of Class A Common Stock held by The Anne Wojcicki Foundation (“AWF”), for which Ms. Wojcicki disclaims beneficial ownership except to the extent of her pecuniary interest therein.
    (3)
    The Trust is the sole member of the LLC and Ms. Wojcicki is the sole trustee of the Trust. Accordingly, the LLC, the Trust, and Ms. Wojcicki have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B Common Stock held by the LLC.
    (4)
    The LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.
    (5)
    Ms. Wojcicki, as the President and Chairman of the Board of AWF, has shared power to vote and dispose, or direct the disposition, of 2,500,000 shares of Class A Common Stock held by AWF.
    (6)
    Includes 98,633,827 shares of the Class A Common Stock that may be obtained upon the conversion of shares of Class B Common Stock held by the reporting persons. Class B Common Stock, which is not registered under the Exchange Act, is convertible into shares of Class A Common Stock on a share-for-share basis.
    (7)
    Based upon (a) 339,502,600 shares of Class A Common Stock outstanding as of July 31, 2024, as disclosed in the Issuer’s Quarterly Report for the quarterly period ended June 30, 2024 filed on Form 10-Q with the SEC on August 8, 2024, (b) 98,633,827 shares of Class A Common Stock issuable upon conversion of the Class B Common Stock held by the LLC, and (c) 8,284,097 shares of Class A Common Stock issuable upon the exercise of options held by Ms. Wojcicki that have vested or will vest within sixty days of the date hereof.

    3


    Explanatory Note
    This Amendment No. 3 (“Amendment No. 3”) to Schedule 13D relates to the Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) of 23andMe Holding Co., a Delaware corporation (the “Issuer”), and amends and supplements the initial statement on Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission (“SEC”) on June 25, 2021, as amended by Amendment No. 1 filed on April 17, 2024, and Amendment No. 2 filed on July 31, 2024 (collectively, the “Initial Schedule 13D”, and as amended and supplemented by this Amendment No. 3, the “Schedule 13D”).  Capitalized terms used but not defined in this Amendment No. 3 shall have the same meanings ascribed to them in the Schedule 13D.
    ITEM 4.  Purpose of the Transaction.
    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
    On September 9, 2024, in response to requests from the Special Committee, Ms. Wojcicki notified the members of the Special Committee that Ms. Wojcicki would be open to considering third party takeover proposals for the Issuer. Ms. Wojcicki continues to evaluate and negotiate a transaction to acquire all of the Issuer’s outstanding shares of common stock not owned by her or her affiliates or any other stockholders she invites to “roll-over” their current equity shares.
    ITEM 5.  Interest in Securities of Issuer.
    Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows:
    (a) The LLC is the record and beneficial owner of 98,633,827 shares of the Issuer’s Class B Common Stock, which may be converted into the same number of shares of Class A Common Stock, representing beneficial ownership of 22.5% of outstanding shares of Class A Common Stock and 59.2 % of the outstanding shares of Class B Common Stock.
     
    The Trust is the sole member of the LLC and therefore may be deemed to beneficially own the 98,633,827 shares of Class B Common Stock held by the LLC, which may be converted into the same number of shares of Class A Common Stock, representing beneficial ownership of 22.5% of the outstanding shares of Class A Common Stock and 59.2% of the outstanding shares of Class B Common Stock.
    Ms. Wojcicki is the sole trustee of the Trust and the President and Chairman of the Board of AWF. Accordingly, Ms. Wojcicki may be deemed the beneficial owner of an aggregate of 110,512,181 shares of Class A Common Stock, consisting of: (a) 1,094,257 shares of Class A Common Stock held directly by Ms. Wojcicki, (b) 8,284,097 stock options held directly by Ms. Wojcicki that have vested or will vest within sixty days of the date hereof, (c) 98,633,827 shares of Class B Common Stock held by the LLC, which may be converted into the number of shares of Class A Common Stock, and (d) 2,500,000 shares of Class A Common Stock held by AWF, representing beneficial ownership of 24.8% of the outstanding shares of Class A Common Stock and 59.2% of the outstanding shares of Class B Common Stock; provided, however, the foregoing amounts include Ms. Wojcicki’s indirect ownership of (i) 98,633,827 shares of Class B Common Stock held by the LLC and (ii) 2,500,000 shares of Class A Common Stock held by AWF, for which Ms. Wojcicki disclaims beneficial ownership except to the extent of her pecuniary interest therein.
    The calculation of the Class A Common Stock beneficial ownership percentages in this Item 5 are based upon (a) 339,502,600 shares of Class A Common Stock outstanding as of July 31, 2024, as disclosed in the Issuer’s Quarterly Report for the quarterly period ended June 30, 2024 filed on Form 10-Q with the SEC on August 8, 2024, and (b) any shares of Class A Common Stock issuable upon the conversion, exercise and/or vesting of Class B Common Stock, stock options, restricted stock units or other convertible securities held by each Reporting Person (including any such securities that have vested or will vest within sixty days of the date hereof), as applicable. The calculation of the Class B Common Stock beneficial ownership percentages are based upon 166,507,453 shares of Class B Common Stock outstanding as of July 31, 2024, as disclosed in the Issuer’s Quarterly Report for the quarterly period ended June 30, 2024 filed on Form 10-Q with the SEC on August 8, 2024.



    By virtue of the relationships described herein, the Reporting Persons may be deemed to constitute a “group” within the meaning of Rule 13d-5 under the Exchange Act. As a member of a group, each Reporting Person may be deemed to share voting and dispositive power with respect to, and therefore beneficially own, the securities of the Issuer beneficially owned by members of the group as a whole. The filing of this Statement on Schedule 13D shall not be construed as an admission that the Reporting Persons beneficially own those securities held by another member of such group. In addition, each Reporting Person expressly disclaims beneficial ownership of any securities reported herein except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities.
    (b) The LLC, the Trust (as the sole member of LLC), and Ms. Wojcicki (as the sole trustee of the Trust) have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B Common Stock held by the LLC. Additionally, the LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.
    Ms. Wojcicki, as the President and Chairman of the Board of AWF, has shared power to vote and dispose, or direct the disposition, of 2,500,000 shares of Class A Common Stock held by AWF. AWF is a 501(c)(3) non-profit organization; its address is 171 Main Street, Suite 259, Los Altos, California 94022. During the last five years, AWF has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, AWF has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and has not been and is not, as a result of such proceeding, subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
    Ms. Wojcicki has sole power to vote and dispose, or direct the disposition, of the securities reported herein as directly held by her.
    (c) There have been no reportable transactions with respect to the Common Stock of the Issuer within the last 60 days by the Reporting Persons, except as described in this Schedule 13D.




    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, the undersigned each certifies that the information with respect to it set forth in this Schedule 13D is true, complete, and correct.
    Dated: September 9, 2024

     
    ABeeC 2.0, LLC
     
           
     
    By:  
    /s/ Ryan Batenchuk
     
       
    Name: Ryan Batenchuk
     
       
    Title: Manager
     
           
     
    THE ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED
     
           
     
    By:  
    /s/ Anne Wojcicki
     
       
    Name: Anne Wojcicki
     
       
    Title: Trustee
     
           
     
    Anne Wojcicki
     
         
     
    /s/ Anne Wojcicki
     

     
    Get the next $ME alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ME

    DatePrice TargetRatingAnalyst
    11/29/2022$7.00Buy
    Berenberg
    9/22/2022$6.00Outperform
    Cowen
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    8/17/2021$13.00Outperform
    Credit Suisse
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    Financials

    Live finance-specific insights

    See more
    • 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

      SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

      11/12/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

      11/7/24 5:54:12 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

      11/7/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

      SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

      3/26/25 6:57:42 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

      Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

      3/23/25 11:08:03 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

      SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

      3/21/25 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on 23andMe with a new price target

      Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00

      11/29/22 7:24:54 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on 23andMe with a new price target

      Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00

      9/22/22 7:20:18 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse reiterated coverage on 23andMe Holding with a new price target

      Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously

      2/11/22 8:14:04 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:48:20 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:20:24 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 23andMe Holding Co.

      SC 13G - 23andMe Holding Co. (0001804591) (Subject)

      11/13/24 6:00:29 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kvarda Matthew

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:38:00 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Walper Thomas B.

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:35:46 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

      4 - 23andMe Holding Co. (0001804591) (Issuer)

      2/21/25 5:05:56 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    SEC Filings

    See more
    • SEC Form 8-K filed by 23andMe Holding Co.

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/28/25 4:09:11 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/24/25 6:23:28 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 23andMe Holding Co.

      10-Q - 23andMe Holding Co. (0001804591) (Filer)

      2/6/25 4:27:52 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Leadership Updates

    Live Leadership Updates

    See more
    • 23andMe Appoints Three New Independent Directors to Board

      SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

      10/29/24 7:30:00 AM ET
      $ANSS
      $CDLX
      $LSCC
      $ME
      Computer Software: Prepackaged Software
      Technology
      Computer Software: Programming Data Processing
      Semiconductors
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

      SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

      5/8/23 7:00:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care